Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate

doi:10.1053/snuc.2001.18742

Seminars in Nuclear Medicine

Volume 31, Issue 1, January 2001, Pages 28-49

https://doi.org/10.1053/snuc.2001.18742 Get rights and content

This article discusses methods for quantifying bone turnover based on tracer kinetic studies of the short-lived radiopharmaceuticals ^99mTc-MDP and ¹⁸F-fluoride. Measurements of skeletal clearance obtained by using these tracers reflect the combined effects of skeletal blood flow and osteoblastic activity. The pharmacokinetics of each tracer is described, together with some of the quantitative tests of skeletal function that have been described in the literature. The physiologic interpretation of quantitative measurements of bone obtained with the use of short half-life radionuclides is discussed, and the advantages and limitations of ^99mTc-MDP and ¹⁸F-fluoride are compared and contrasted. Currently, ¹⁸F-fluoride dynamic positron emission tomography (PET) is the technique of choice for physiologically precise quantitative studies of bone. However, comparable data could probably be obtained by using ^99mTc-MDP if methods for single photon emission computed tomography (SPECT) quantitation were improved.

References (140)

BlakeGM et al.
Technical principles of dual energy X-ray absorptiometry
Semin Nucl Med
(1997)
BlakeGM et al.
Interpretation of bone densitometry studies
Semin Nucl Med
(1997)
JungA et al.
Critical analysis of methods for analysing human calcium kinetics
J Theor Biol
(1978)
WeaverCM
Use of calcium tracers and biomarkers to determine calcium kinetics and bone turnover
Bone
(1998)
BlauM et al.
¹⁸F-fluoride for bone imaging
Semin Nucl Med
(1972)
LinJH
Bisphosphonates: A review of their Pharmacokinetics properties
Bone
(1996)
RussellRG et al.
Bisphosphonates: From the laboratory to the clinic and back again
Bone
(1999)
JonesAG et al.
Bone scanning: Radionuclidic reaction mechanisms
Semin Nucl Med
(1976)
DavisMA et al.
Comparison of ^99mTc-labeled phosphate and phosphonate agents for skeletal imaging
Semin Nucl Med
(1976)
MundyGR et al.
The hypercalcaemia of malignancy: Pathogenesis and treatment
Metabolism
(1982)

HamdyNAT et al.

The palliative management of skeletal metastases in prostate cancer: Use of boneseeking radionuclides and bisphosphonates

Semin Nucl Med

(2001)

EdelmanIS et al.

Anatomy of body water and electrolytes

Am J Med

(1959)

FogelmanI et al.

Skeletal uptake of disphosphonate. Method for prediction of postmenopausal osteoporosis

Lancet

(1980)

AndrewsGA et al.

Whole-body counting

Semin Nucl Med

(1973)

EinhornTA

The bone organ system: Form and function

BaronR

Anatomy and ultrastructure of bone

SabatierJP et al.

Evolution of lumbar bone mineral content during adolescence and adulthood: A longitudinal study in 395 healthy females 10–24 years of age and 206 premenopausal women

Osteoporos Int

(1999)

BassS et al.

The differing tempo of growth in bone size, mass, and density is region-specific

J Clin Invest

(1999)

HuiSL et al.

Rates of growth and loss of bone mineral in the spine and femoral neck in white females

Osteoporos Int

(1999)

KhoslaS et al.

Biochemical markers of bone turnover

GarneroP et al.

Measurements of biochemical markers: Methods and limitations

SeibelMJ et al.

Clinical applications of biochemical markers of bone metabolism

GarneroP et al.

Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment

J Clin Endocrinol Metab

(1994)

Beck-JensenJE et al.

A single measurement of biochemical markers of bone turnover has limited utility in the individual person

Scand J Clin Lab Invest

(1997)

ReckerRR

Bone biopsy and histomorphometry in clinical practice

MillerPD et al.

Clinical applications of bone densitometry

EastellR

Treatment of postmenopausal osteoporosis

N Engl J Med

(1998)

MarshallJH et al.

Alkaline earth metabolism in adult man

Health Phys

(1973)

SubramanianG et al.

Technetium-99m-methylene disphosphonate—A superior agent for skeletal imaging: Comparison with other technetium complexes

J Nucl Med

(1975)

PetersAM

Bone turnover in osteoporosis

SubramanianG

Radiopharmaceuticals for bone scanning

FrancisMD et al.

Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo

Science

(1969)

SirisES

Paget's disease of bone

LibermanUA et al.

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis

N Engl J Med

(1995)

MortensenL et al.

Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up

J Clin Endocrinol Metab

(1998)

BlackDM et al.

Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures

Lancet

(1996)

ReginsterJ-Y et al.

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis

Osteoporos Int

(2000)

HortobagyiGN et al.

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases

N Engl J Med

(1996)

HyldstrupL et al.

Studies on diphosphonate kinetics. Part I: Evaluation of plasma elimination curves during 24 h

Eur J Nucl Med

(1987)

HyldstrupL et al.

Studies on diphosphonate kinetics. Part II: Whole body bone uptake rate during constant infusion—A refined index of bone metabolism

Eur J Nucl Med

(1987)

NisbetAP et al.

Chromium-51 EDTA/technetium-99m-MDP plasma ratio to measure total skeletal function

Br J Radiol

(1984)

WhitfordGM

Intake and metabolism of fluoride

Adv Dent Res

(1994)

PiersonRN et al.

Extracellular water measurements: Organ tracer kinetics of bromide and sucrose in rats and man

Am J Physiol

(1978)

StaffurthJS et al.

The measurement of the extracellular fluid volume with radioactive bromine

Clin Sci

(1960)

TostesonDC

Halide transport in red blood cells

Acta Physiol Scand

(1959)

HoskingDJ et al.

Studies in man with ¹⁸F

Clin Sci

(1972)

WoottonR et al.

The single-passage extraction of ¹⁸F in rabbit bone

Clin Phys Physiol Meas

(1986)

HawkinsRA et al.

Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET

J Nucl Med

(1992)

Cited by (264)

The role of conventional and novel PET radiotracers in assessment of myeloma bone disease
2024, Bone
Over 80 % of patients with multiple myeloma (MM) experience osteolytic bone lesions, primarily due to an imbalanced interaction between osteoclasts and osteoblasts. This imbalance can lead to several adverse outcomes such as pain, fractures, limited mobility, and neurological impairments. Myeloma bone disease (MBD) raises the expense of management in addition to being a major source of disability and morbidity in myeloma patients. Whole-body x-ray radiography was the gold standard imaging modality for detecting lytic lesions. Osteolytic lesions are difficult to identify at an earlier stage on X-ray since the lesions do not manifest themselves on conventional radiographs until at least 30 % to 50 % of the bone mass has been destroyed. Hence, early diagnosis of osteolytic lesions necessitates the utilization of more complex and advanced imaging modalities, such as PET. One of the PET radiotracers that has been frequently investigated in MM is ¹⁸F-FDG, which has demonstrated a high level of sensitivity and specificity in detecting myeloma lesions. However, ¹⁸F-FDG PET/CT has several restrictions, and therefore the novel PET tracers that can overcome the limitations of ¹⁸F-FDG PET/CT should be further examined in assessment of MBD. The objective of this review article is to thoroughly examine the significance of both conventional and novel PET radiotracers in the assessment of MBD. The intention is to present the information in a manner that would be easily understood by healthcare professionals from diverse backgrounds, while minimizing the use of complex nuclear medicine terminology.
SPECT/CT and PET/CT for the Evaluation of Persistent or Recurrent Pain After Spine Surgery: A Systematic Review and Case Series
2024, World Neurosurgery
The differential diagnosis for postoperative back pain is broad, and conventional imaging modalities are not always conclusive. Therefore, we performed a systematic review of the literature and present case studies describing the use of single-photon emission CT (SPECT)/CT or positron emission tomography (PET)/CT in the diagnosis of back pain following spine surgery.
A systematic review was conducted according to PRISMA guidelines across 5 databases. Relevant keywords included PET/CT, bone SPECT/CT, and pseudarthrosis. The studies were assessed for diagnostic accuracy of the imaging technologies.
A total of 2,444 studies were screened, 91 were selected for full-text review, and 21 were ultimately included. Six retrospective studies investigated the use of SPECT/CT with a total sample size of 309 patients. Two of these studies used SPECT/CT to predict screw loosening in over 50% of patients. Eight studies examined the use of 18-fluoride sodium fluoride (18F-NaF) PET/CT. Among these studies, measures of diagnostic accuracy varied but overall demonstrated the ability of 18F-NaF PET/CT to detect screw loosening and pseudarthrosis. Seven studies examined 18F-fluorodeoxyglucose (FDG) PET/CT and supported its utility in the diagnosis of postoperative infections in the spine.
PET/CT and SPECT/CT are useful in the evaluation of postoperative pain of the spine, especially in patients for whom conventional imaging modalities yield inconclusive results. More diagnostic accuracy studies with strong reference standards are needed to compare hybrid imaging to conventional imaging.
Alternatives to PSMA-ligands for PET imaging of prostate cancer
2023, Medecine Nucleaire
La TEP/TDM ciblant l’antigène membranaire spécifique de la prostate (PSMA) est la technique d’imagerie de choix du cancer de prostate. Elle a cependant des limites. L’objectif de cette revue est de présenter les radiotraceurs, autres que ceux ciblant le PSMA, pour l’imagerie TEP du cancer de prostate.
Prostate specific membrane antigen (PSMA) PET/CT imaging is the preferred technique for prostate cancer imaging. However, prostate cancer is a heterogeneous disease and PSMA PET can be negative in some patients. Furthermore, a significant number of patients treated with radioligand therapy targeting PSMA experience treatment failure. The objective of this review is to present alternative PET radiotracers, other than those targeting PSMA.
<sup>18</sup>F-Sodium Fluoride PET/CT in Assessing Valvular Heart and Atherosclerotic Diseases
2023, Seminars in Nuclear Medicine
Aortic valve stenosis is the most common valvular disease in Western countries, while atherosclerotic cardiovascular disease is the foremost cause of death and disability worldwide. Valve degeneration and atherosclerosis are mediated by inflammation and calcification and inevitably progress over time. Computed tomography can visualise the later stages of macroscopic calcification but fails to assess the early stages of microcalcification and cannot differentiate active from burnt out disease states. Molecular imaging has the ability to provide complementary information related to disease activity, which may allow us to detect disease early, to predict disease progression and to monitor preventive or therapeutic strategies for in both aortic stenosis and atherosclerosis. PET/CT is a non-invasive imaging technique that enables visualization of ongoing molecular processes within small structures, such as the coronary arteries or heart valves. ¹⁸F-sodium fluoride (¹⁸F-NaF) binds hydroxyapatite deposits in the extracellular matrix, with preferential binding to newly developing deposits of microcalcification, which provides an assessment of calcification activity. In recent years, ¹⁸F-NaF has attracted the attention of many research groups and has been evaluated in several pathological cardiovascular processes. Histologic validation of the ¹⁸F-NaF PET signal in valvular disease and atherosclerosis has been reported in multiple independent studies. The selective high-affinity binding of ¹⁸F-NaF to microscopic calcified deposits (beyond the resolution of μCT) has been demonstrated ex vivo, as well as its ability to distinguish between areas of macro- and active microcalcification. In addition, prospective clinical studies have shown that baseline ¹⁸F-NaF uptake in patients with aortic stenosis and mitral annular calcification is correlated with subsequent calcium deposition and valvular dysfunction after a follow-up period of 2 years. In patients with surgical bioprosthetic aortic valves but without morphological criteria for prosthetic degeneration, increased ¹⁸F-NaF uptake at baseline was associated with subsequent bioprosthetic degeneration over time. Similar data were obtained in a cohort of patients with transcatheter aortic valve implantation. Furthermore, several studies have confirmed the association of coronary ¹⁸F-NaF uptake with adverse atherosclerotic plaque features, active disease and future disease progression. ¹⁸F-NaF uptake is also associated with future fatal or nonfatal myocardial infarction in patients with established coronary artery disease. The link between ¹⁸F-NaF uptake and active atherosclerotic disease has not only been demonstrated in the coronary arteries, but also in peripheral arterial disease, abdominal aortic aneurysms and carotid atherosclerosis. It can be assumed that ¹⁸F-NaF PET/CT will strengthen the diagnostic toolbox of practitioners in the coming years. Indeed, there is a strong medical need to diagnose degenerative valvular disease and to detect active atherosclerotic disease states. Finally, the use of ¹⁸F-NaF as a biomarker to monitor the efficacy of drug therapies in preventing these pathological processes is attractive. In this review, we consider the role of ¹⁸F-NaF PET/CT imaging in cardiac valvular diseases and atherosclerosis.
Imaging of Bone Metastases in Breast Cancer
2022, Seminars in Nuclear Medicine
Bone metastases are a common site of spread in advanced breast cancer and responsible for morbidity and high health care costs. Imaging contributes to staging and response assessment of the skeleton and has been instrumental in guiding patient management for several decades. Historically this has been with radiographs, computed tomography and bone scans. More recently, molecular and hybrid imaging methods have undergone significant development, including the addition of single photon emission computed tomography/computed tomography to the bone scan, positron emission tomography, with bone-specific and tumor-specific tracers, and magnetic resonance imaging with complementary functional diffusion-weighted imaging. These have allowed different aspects of the abnormal biology associated with bone metastases to be explored. There is ability to interrogate the bone microenvironment with bone-specific tracers and cancer cell characteristics with tumor-specific methods that complement morphological appearances on computed tomography or magnetic resonance imaging. Alongside the advent of novel, more effective and nuanced therapies for bone metastases in breast cancer, there is accumulating evidence that the developments in imaging allow more sensitive and specific detection of bone metastases as well as more accurate and earlier assessment of treatment response leading to improvements in patient management.
Estimation of additional dosimetry from low-dose CT scan to <sup>99m</sup>Tc-HMDP SPECT/CT
2022, Journal of Medical Imaging and Radiation Sciences
Citation Excerpt :
Whole-body bone scintigraphy with hydroxymethylenediphosphonate labelled with technetium 99 metastable (99mTc-HMDP) is the most common method for diagnosing bone metastases. It is a widely used procedure that provides a study of the whole body skeleton at a relatively low cost [4-6]. Compared to other imaging methods, it has good diagnostic efficiency [8].
Currently, the addition of computed tomography (CT) to a gamma-camera has revolutionized nuclear medicine. Indeed the CT, because of its good spatial resolution, of the attenuation correction of the single photon emission computed tomography (SPECT) images and of a better anatomical localization of lesions, improves the sensitivity, specificity and accuracy of the examination. Despite the fact that the hybrid camera uses a low-dose non-diagnostic scanner, increases the overall delivered dose of radiation.
The aim of this study was to evaluate the contribution of CT to the total effective dose of ^99mTc-HMDP (hydroxymethylenediphosphonate labelled with technetium 99 metastable) SPECT/CT for an adult oncologic population. This prospective study included 103 patients (75 women and 28 men) aged 28 to 79 years.
The mean effective doses of SPECT, CT and SPECT/CT were respectively 3.8 mSv, 3.3 mSv and 7.1 mSv, respectively. The average contribution of CT scans to the total effective dose for SPECT/CT examination was 45 ± 9.7%, and ranged from 10 to 67.4%. The lowest value was for the thorax area.
This radiation dose is not negligible. But, taking into account the benefit of hybrid imaging, this additional radiation remains justifiable. Nevertheless, the "As Low as Reasonably Achievable (ALARA)'' principle must be respected to ensure that the patient is not subjected to unnecessarily high levels of radiation.
L'ajout de la tomodensitométrie (TDM) à une gamma-caméra a révolutionné la médecine nucléaire. En effet, la TDM, grâce à sa bonne résolution spatiale, à la correction de l'atténuation des images de tomographie par émission monophotonique (TEMP) et à une meilleure localisation anatomique des lésions, améliore la sensibilité, la spécificité et la précision de l'examen. Malgré le fait que la caméra hybride utilise un scanner non diagnostique faible dose, elle augmente la dose globale d'irradiation.
L'objectif de cette étude était d'évaluer la contribution de la TDM à la dose efficace totale TEMP-TDM au ^99mTc-HMDP (hydroxyméthylènediphosphonate marqué au technétium 99 métastable) pour une population oncologique adulte. Cette étude prospective a inclus 103 patients (75 femmes et 28 hommes) âgés de 28 à 79 ans.
Les doses efficaces moyennes de la TEMP, de la TDM et de la TEMP-TDM étaient respectivement de 3,8 mSv, 3,3 mSv et 7,1 mSv. La contribution moyenne de la TDM à la dose efficace totale de la TEMP/TDM était de 45 ± 9,7 %, et variait de 10 à 67,4 %. La valeur la plus faible concernait la région thoracique.
Cette dose d'irradiation n'est pas négligeable. Mais, compte tenu du bénéfice de l'imagerie hybride, cette irradiation supplémentaire reste justifiable. Néanmoins, le principe ALARA (As Low as Reasonably Achievable) doit être respecté pour s'assurer que le patient n'est pas soumis à des niveaux d'irradiation inutilement élevés.

View all citing articles on Scopus

View full text

Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate

Semin Nucl Med

Semin Nucl Med

J Theor Biol

Bone

Semin Nucl Med

Bone

Bone

Semin Nucl Med

Semin Nucl Med

Metabolism

Semin Nucl Med

Am J Med

Lancet

Semin Nucl Med

The bone organ system: Form and function

Anatomy and ultrastructure of bone

Evolution of lumbar bone mineral content during adolescence and adulthood: A longitudinal study in 395 healthy females 10–24 years of age and 206 premenopausal women

Osteoporos Int

The differing tempo of growth in bone size, mass, and density is region-specific

J Clin Invest

Rates of growth and loss of bone mineral in the spine and femoral neck in white females

Osteoporos Int

Biochemical markers of bone turnover

Measurements of biochemical markers: Methods and limitations

Clinical applications of biochemical markers of bone metabolism

Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment

J Clin Endocrinol Metab

A single measurement of biochemical markers of bone turnover has limited utility in the individual person

Scand J Clin Lab Invest

Bone biopsy and histomorphometry in clinical practice

Clinical applications of bone densitometry

Treatment of postmenopausal osteoporosis

N Engl J Med

Alkaline earth metabolism in adult man

Health Phys

Technetium-99m-methylene disphosphonate—A superior agent for skeletal imaging: Comparison with other technetium complexes

J Nucl Med

Bone turnover in osteoporosis

Radiopharmaceuticals for bone scanning

Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo

Science

Paget's disease of bone

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis

N Engl J Med

Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up

J Clin Endocrinol Metab

Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures

Lancet

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis

Osteoporos Int

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases

N Engl J Med

Studies on diphosphonate kinetics. Part I: Evaluation of plasma elimination curves during 24 h

Eur J Nucl Med

Studies on diphosphonate kinetics. Part II: Whole body bone uptake rate during constant infusion—A refined index of bone metabolism

Eur J Nucl Med

Chromium-51 EDTA/technetium-99m-MDP plasma ratio to measure total skeletal function

Br J Radiol

Intake and metabolism of fluoride

Adv Dent Res

Extracellular water measurements: Organ tracer kinetics of bromide and sucrose in rats and man

Am J Physiol

The measurement of the extracellular fluid volume with radioactive bromine

Clin Sci

Halide transport in red blood cells

Acta Physiol Scand

Studies in man with 18F

Clin Sci

The single-passage extraction of 18F in rabbit bone

Clin Phys Physiol Meas

Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET

J Nucl Med

Quantitative studies of bone with the use of ¹⁸F-fluoride and ^99mTc-methylene diphosphonate

Studies in man with ¹⁸F

The single-passage extraction of ¹⁸F in rabbit bone